Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tara Cronin

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Trends in Ecology & Evolution|October 7, 2025
Disability in ecology and evolutionJohn J Dennehy, Tara Cronin
Leukemia|November 3, 2023
ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasmsHassan Awada, Manasa Bhatta, Han Yu, et al.
Leukemia & Lymphoma|December 27, 2024
Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignanciesJeffrey Baron, Daniel Appiah, Mark G Faber, et al.
Leukemia Research|February 12, 2025
Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapySawyer Bawek, Matthew Burwinkel, Prutha Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 25, 2021
Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy BackboneAbhay Singh, Swapna Thota, Terrence Bradley, et al.
Blood Cancer Journal|September 4, 2023
Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemiaHassan Awada, Mina Abdelmalek, Tara Cronin, et al.
Leukemia|January 29, 2021
Germline variants drive myelodysplastic syndrome in young adultsSimone Feurstein, Jane E Churpek, Tom Walsh, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Trends in Ecology & Evolution|October 7, 2025
Disability in ecology and evolutionJohn J Dennehy, Tara Cronin
Leukemia|November 3, 2023
ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasmsHassan Awada, Manasa Bhatta, Han Yu, et al.
Leukemia & Lymphoma|December 27, 2024
Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignanciesJeffrey Baron, Daniel Appiah, Mark G Faber, et al.
Leukemia Research|February 12, 2025
Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapySawyer Bawek, Matthew Burwinkel, Prutha Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 25, 2021
Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy BackboneAbhay Singh, Swapna Thota, Terrence Bradley, et al.
Blood Cancer Journal|September 4, 2023
Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemiaHassan Awada, Mina Abdelmalek, Tara Cronin, et al.
Leukemia|January 29, 2021
Germline variants drive myelodysplastic syndrome in young adultsSimone Feurstein, Jane E Churpek, Tom Walsh, et al.
Pageof 1